Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-induced molecular changes in metastatic breast cancer
ACTRN12609000904279Phase 2Recruiting
- Sponsor
- Georgios Kesisis
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in breast cancer, sponsored by Georgios Kesisis. Started Oct 2009; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12609000904279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000904279.